Diffuse Large B-cell Lymphoma

Patients with DLBCL were at an increased risk of non-cancer-related deaths from blood disease, infection, gastrointestinal disease, vascular diseases, and lung disease.

Data suggest that lenalidomide maintenance for 24 months can prolong PFS among elderly patients with DLBCL, but does not improve overall survival.

Two SNPS (rs4880 and rs1870377) had an association with PFS among patients with DLBCL receiving R-CHOP.

Glucocorticoid-containing chemotherapy may induce diabetes mellitus or worsen glucose control among patients with diffuse large B cell lymphoma.

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Patients with diffuse large B-cell lymphoma (DLBCL) who achieved post-treatment event-free survival for 24 months had only a minimally lower life expectancy.

For relapsed or refractory diffuse large B-cell lymphoma (DLBCL), there is no difference in efficacy between ofatumumab or rituximab.

Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.